Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304083 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
A Phase 2 study of Sarcoma and Neurofibromatosis Type 1, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 17
- Study locations
NCT00304083 is a Phase 2 study of Sarcoma and Neurofibromatosis Type 1 that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 48 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT00304083, a Phase 2 study of Sarcoma and Neurofibromatosis Type 1, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 17
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy with or without radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with stage III or stage IV malignant peripheral nerve sheath tumors.
Conditions Studied
Interventions
- DRUG etoposide
- PROCEDURE conventional surgery
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Study Locations (17)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Pennsylvania Oncology Hematology Associates - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
Maryland
- Johns Hopkins - Baltimore
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Alabama
- UAB Comprehensive Cancer Center - Birmingham
California
- Sarcoma Oncology Center - Santa Monica
Illinois
- Children's Memorial Hospital - Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00304083
The ClinicalTrials.gov registry entry for NCT00304083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT00304083 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Pennsylvania, Maryland, Alabama.
Frequently Asked Questions
What is clinical trial NCT00304083 about?
NCT00304083 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors". RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemothera...
What is the current status of trial NCT00304083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-12. Estimated completion is 2014-06.
What conditions does trial NCT00304083 study?
This clinical trial studies the following conditions: Sarcoma, Neurofibromatosis Type 1.
What interventions are being tested in trial NCT00304083?
The interventions under investigation include: etoposide (DRUG), conventional surgery (PROCEDURE), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00304083?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00304083 being conducted?
This trial has 17 study locations across Alabama, California, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.